Skip to main content

Gloria Melanie's Form 4 filing

Immunovant, Inc. (IMVT) · filed Nov 21, 2025

Accession no.
0001764013-25-000156
Filed
Nov 21, 2025
Trade date
Nov 20, 2025
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $298.2K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gloria MelanieCIK 0001973838Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 20, 2025Common StockSSaleDisposed−10,251$23.54F2−$241,308.54175,886Direct
Nov 20, 2025Common StockSSaleDisposed−2,375$23.97F3−$56,928.75173,511Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.93 - $23.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.93 - $24.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit List - Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)